Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus

Michele B. Kaufman, PharmD, BCGP  |  Issue: June 2022  |  May 5, 2022

ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric Morand, MD, head of the School of Clinical Sciences, Monash University, and director of Rheumatology, Monash Health, Melbourne, Australia.

Anifrolumab is a type I interferon receptor antagonist.3 On July 30, 2021, the U.S. Food & Drug Administration (FDA) approved anifrolumab for the treatment of adults with moderate to severe SLE who were also receiving standard therapy.4,5 (Note: See below for how this was defined.) The FDA approval was based on both TULIP trials.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The phase 3 TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) studies were randomized, placebo-controlled, 52-week trials during which 300 mg of intravenous anifrolumab was given every four weeks for 48 weeks to eligible patients with moderate to severe SLE despite standard therapy (i.e., treatment with at least one of the following agents or classes: oral glucocorticoids; antimalarials; and/or immunosuppressive agents, such as methotrexate, azathioprine and/or mycophenolate mofetil).

The study included patients classified as having SLE according to the ACR’s 1997 criteria. All patients were at least 18 years old and had moderate to severe disease, with an SLE Disease Activity Index 2000 (SLEDAI-2K) score of at least 6 points, organ-level involvement based on the British Isles Lupus Assessment Group (BILAG) assessment and a Physician’s Global Assessment (PGA) score of at least 1. During the studies, patients continued their existing SLE therapy at stable doses, except for patients receiving oral glucocorticoids, which were tapered.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The BILAG index is a standardized SLE disease activity assessment. Efficacy in the TULIP trials was demonstrated using the BILAG-based Combined Lupus Assessment (BICLA) response, which includes reducing all severe or moderately severe disease activity, no worsening in other organ systems, no worsening in disease activity, no discontinuation of the trial intervention and no use of restricted medications beyond those allowed in the protocol.

Pooled data for the 300 mg of anifrolumab (n=360) and placebo (n=366) groups were analyzed by time point for achieving a lupus low disease activity state (LLDAS), defined as:

  • An SLEDAI-2K score of 4 or less without major organ activity;
  • No new disease activity;
  • A PGA score (0–3) of 1 or less;
  • Prednisone or equivalent glucocorticoid use of less than or equal to 7.5 mg/day; and
  • Tolerating standard immunosuppressant dosing.

The time to achieving LLDAS was compared between treatment groups using Cox regression. The cumulative time to LLDAS was compared using a Cochran–Mantel–Haenszel approach, and responses were compared using logistic regression. All P-values are nominal.

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2021anifrolumabSLEsystemic lupus erythematosus (SLE)

Related Articles

    Anifrolumab Promising for SLE

    December 13, 2019

    Recent research has found a higher does of anifrolumab may benefit patients with moderate to severe SLE…

    Study Says Low Disease-Activity State Can Reduce Lupus Organ Damage

    October 18, 2018

    Over time, systemic lupus erythematosus (SLE) can lead to considerable organ damage. Preventing this outcome is complicated by a scarcity of treatment options that can drive the disease into remission and by the side effects of existing therapies, such as prednisone and other corticosteroids, which may themselves contribute to the long-term damage. The largest study…

    A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review

    December 7, 2020

    During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.

    Insight into Clinical Trials for Lupus

    June 12, 2019

    Research into lupus treatments suffered a setback after the failure of anifrolumab in clinical trials. However, during the 2019 ACR State-of-the-Art Clinical Symposium, Richard Furie, MD, outlined the possibilities of multiple new lupus therapies under investigation…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences